Selected article for: "cohort study and negative control outcome"

Author: Sainsbury, Christopher; Wang, Jingya; Gokhale, Krishna; Acosta‐Mena, Dionisio; Dhalla, Samir; Byne, Nathan; Chandan, Joht Singh; Anand, Astha; Cooper, Jennifer; Okoth, Kelvin; Subramanian, Anuradhaa; Bangash, Mansoor N; Taverner, Thomas; Hanif, Wasim; Ghosh, Sandip; Narendran, Parth; Cheng, Kar Keung; Marshall, Tom; Gkoutos, Georgios; Toulis, Konstantinos; Thomas, Neil; Tahrani, Abd; Adderley, Nicola J; Haroon, Shamil; Nirantharakumar, Krishnarajah
Title: Sodium‐glucose‐co‐transporter‐2 inhibitors and susceptibility to COVID‐19: a population‐based retrospective cohort study
  • Cord-id: y02arv25
  • Document date: 2020_9_29
  • ID: y02arv25
    Snippet: Sodium/glucose co‐transporter‐2 inhibitors (SGLT2i) are widely prescribed in people with type 2 diabetes. We aimed to investigate whether SGLT2i prescription is associated with COVID‐19, when compared with an active comparator. We performed a propensity score‐matched cohort study with active comparators and a negative control outcome in a large UK‐based primary care dataset. Participants prescribed SGLT2i (n = 9948) and a comparator group prescribed dipeptyl‐peptidase 4 inhibitors (D
    Document: Sodium/glucose co‐transporter‐2 inhibitors (SGLT2i) are widely prescribed in people with type 2 diabetes. We aimed to investigate whether SGLT2i prescription is associated with COVID‐19, when compared with an active comparator. We performed a propensity score‐matched cohort study with active comparators and a negative control outcome in a large UK‐based primary care dataset. Participants prescribed SGLT2i (n = 9948) and a comparator group prescribed dipeptyl‐peptidase 4 inhibitors (DPP4i; n = 14 917) were followed up from 30th January to 27th July 2020. The primary outcome was confirmed or clinically suspected COVID‐19. The incidence rate of COVID‐19 was 19.7/1000 person‐years among users of SGLT2i and 24.7/1000 person‐years among propensity score matched users of DPP4i. The adjusted hazard ratio was 0.92 (95% CI 0.66 to 1.29) and there was no evidence of residual confounding in the negative control analysis. We did not observe an increased risk of COVID‐19 in primary care amongst those prescribed SGLT2i compared to DPP4i, suggesting that clinicians may safely use these agents in the everyday care of people with type 2 diabetes during the COVID‐19 pandemic. This article is protected by copyright. All rights reserved.

    Search related documents:
    Co phrase search for related documents